Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression

D. S. Sun, Takahito Yagi, T. Oyama, H. Matsukawa, H. Matsuda, H. Sadamori, M. Inagaki, Junji Matsuoka, H. Iwagaki, N. Tanaka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Donor-specific immunosuppression is important in transplant surgery. We examined the effect of intraportal donor-specific bone marrow transplantation on heterotopic small bowel transplantation in the high responder rat combination, ACI to Lewis. The study comprised five treatment groups: untreated controls (group 1); FK506 alone (group 2); low-dose predonine + FK506 (group 3); high-dose predonine + FK506 (group 4); and intraportal donor-specific bone marrow transplantation + FK506 (group 5). Intraportal transplantation was performed pre-operatively and FK506 and predonine given postoperatively. Intestinal allograft survival and changes of intragraft cytokine expression were analysed using the reverse transcription polymerase chain reaction. Allograft survival (mean ± SD) was lowest in group 1 and greatest in group 5. The group 5 treatment regimen also down-regulated interferon-γ and interleukin-2 transcription in the transplanted intestine. Intraportal donor bone marrow transplant combined with FK506 immunosuppression was found therefore to be the most beneficial treatment regimen.

Original languageEnglish
Pages (from-to)281-289
Number of pages9
JournalJournal of International Medical Research
Volume31
Issue number4
Publication statusPublished - Jul 2003

Fingerprint

Tacrolimus
Bone Marrow Transplantation
Immunosuppression
Allografts
Rats
Bone
Prednisolone
Transplants
Transcription
Inbred ACI Rats
Transplantation
Polymerase chain reaction
Surgery
Interferons
Reverse Transcription
Intestines
Interleukin-2
Therapeutics
Bone Marrow
Cytokines

Keywords

  • Bone marrow transplantation
  • FK506
  • Interferon (IFN)-γ
  • Interleukin (IL)-2
  • Small bowel transplantation
  • Steroids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression. / Sun, D. S.; Yagi, Takahito; Oyama, T.; Matsukawa, H.; Matsuda, H.; Sadamori, H.; Inagaki, M.; Matsuoka, Junji; Iwagaki, H.; Tanaka, N.

In: Journal of International Medical Research, Vol. 31, No. 4, 07.2003, p. 281-289.

Research output: Contribution to journalArticle

Sun, DS, Yagi, T, Oyama, T, Matsukawa, H, Matsuda, H, Sadamori, H, Inagaki, M, Matsuoka, J, Iwagaki, H & Tanaka, N 2003, 'Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression', Journal of International Medical Research, vol. 31, no. 4, pp. 281-289.
Sun, D. S. ; Yagi, Takahito ; Oyama, T. ; Matsukawa, H. ; Matsuda, H. ; Sadamori, H. ; Inagaki, M. ; Matsuoka, Junji ; Iwagaki, H. ; Tanaka, N. / Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression. In: Journal of International Medical Research. 2003 ; Vol. 31, No. 4. pp. 281-289.
@article{9ce7c2383b924eada37167dca5d9282c,
title = "Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression",
abstract = "Donor-specific immunosuppression is important in transplant surgery. We examined the effect of intraportal donor-specific bone marrow transplantation on heterotopic small bowel transplantation in the high responder rat combination, ACI to Lewis. The study comprised five treatment groups: untreated controls (group 1); FK506 alone (group 2); low-dose predonine + FK506 (group 3); high-dose predonine + FK506 (group 4); and intraportal donor-specific bone marrow transplantation + FK506 (group 5). Intraportal transplantation was performed pre-operatively and FK506 and predonine given postoperatively. Intestinal allograft survival and changes of intragraft cytokine expression were analysed using the reverse transcription polymerase chain reaction. Allograft survival (mean ± SD) was lowest in group 1 and greatest in group 5. The group 5 treatment regimen also down-regulated interferon-γ and interleukin-2 transcription in the transplanted intestine. Intraportal donor bone marrow transplant combined with FK506 immunosuppression was found therefore to be the most beneficial treatment regimen.",
keywords = "Bone marrow transplantation, FK506, Interferon (IFN)-γ, Interleukin (IL)-2, Small bowel transplantation, Steroids",
author = "Sun, {D. S.} and Takahito Yagi and T. Oyama and H. Matsukawa and H. Matsuda and H. Sadamori and M. Inagaki and Junji Matsuoka and H. Iwagaki and N. Tanaka",
year = "2003",
month = "7",
language = "English",
volume = "31",
pages = "281--289",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "4",

}

TY - JOUR

T1 - Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression

AU - Sun, D. S.

AU - Yagi, Takahito

AU - Oyama, T.

AU - Matsukawa, H.

AU - Matsuda, H.

AU - Sadamori, H.

AU - Inagaki, M.

AU - Matsuoka, Junji

AU - Iwagaki, H.

AU - Tanaka, N.

PY - 2003/7

Y1 - 2003/7

N2 - Donor-specific immunosuppression is important in transplant surgery. We examined the effect of intraportal donor-specific bone marrow transplantation on heterotopic small bowel transplantation in the high responder rat combination, ACI to Lewis. The study comprised five treatment groups: untreated controls (group 1); FK506 alone (group 2); low-dose predonine + FK506 (group 3); high-dose predonine + FK506 (group 4); and intraportal donor-specific bone marrow transplantation + FK506 (group 5). Intraportal transplantation was performed pre-operatively and FK506 and predonine given postoperatively. Intestinal allograft survival and changes of intragraft cytokine expression were analysed using the reverse transcription polymerase chain reaction. Allograft survival (mean ± SD) was lowest in group 1 and greatest in group 5. The group 5 treatment regimen also down-regulated interferon-γ and interleukin-2 transcription in the transplanted intestine. Intraportal donor bone marrow transplant combined with FK506 immunosuppression was found therefore to be the most beneficial treatment regimen.

AB - Donor-specific immunosuppression is important in transplant surgery. We examined the effect of intraportal donor-specific bone marrow transplantation on heterotopic small bowel transplantation in the high responder rat combination, ACI to Lewis. The study comprised five treatment groups: untreated controls (group 1); FK506 alone (group 2); low-dose predonine + FK506 (group 3); high-dose predonine + FK506 (group 4); and intraportal donor-specific bone marrow transplantation + FK506 (group 5). Intraportal transplantation was performed pre-operatively and FK506 and predonine given postoperatively. Intestinal allograft survival and changes of intragraft cytokine expression were analysed using the reverse transcription polymerase chain reaction. Allograft survival (mean ± SD) was lowest in group 1 and greatest in group 5. The group 5 treatment regimen also down-regulated interferon-γ and interleukin-2 transcription in the transplanted intestine. Intraportal donor bone marrow transplant combined with FK506 immunosuppression was found therefore to be the most beneficial treatment regimen.

KW - Bone marrow transplantation

KW - FK506

KW - Interferon (IFN)-γ

KW - Interleukin (IL)-2

KW - Small bowel transplantation

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=10744228624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228624&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 281

EP - 289

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 4

ER -